SangStat creating a niche in transplant market

SangStat creating a niche in transplant market

SangStat Medical Corp. was to announce today that it has filed for Canadian marketing approval of Thymoglobulin, a rabbit-derived polyclonal antibody for prophylaxis of solid organ transplant rejection.

The filing puts in place another piece in the company's strategy of rapid commercialization of transplantation products. And it comes just as the company's partner, Baxter, has raised the ante by forming its own broad-based product platform for the transplantation market.

SANG already has one commercial product,

Read the full 807 word article

How to gain access

Continue reading with a
two-week free trial.